In 2014

TIEN (Tianjin) Pharmaceutical’s Phase I project, API manufacturing facility, completed and started operation;

In 2015

Register DMF  in USA

In 2017

“Cloprostenol sodium” API passed US FDA site inspection with “0” 483；

In 2018

Register API in the European Union

In Jan, 2021

Phase II formulation facility (6000㎡) completed; 

In Jul, 2021

“Carboprost TMA” API passed GMP site inspection by NMPA and Dynamic Batch Production audit by CDE; commercially launched; 

In Dec, 2021

“Cloprostenol sodium” approved by EU regulatory authority; 

In Feb, 2022

“Alprostadil”API received CDE approval and site inspection for GMP compliance before commercial;

In jun, 2022

Our first small volume injection drug “Cloprostenol sodium injection” received approval by MAC for reproductive hormone therapy in Veterinary application.